GlassScriptPhysician profile
Douglas J Black
NPI 1598753832
$1,635.56
in general payments reported to CMS, 2019-2025
18 companies · $28.94 in 2025
The $28.94 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.20 · 2022: $842 · 2023: $717 · 2025: $28.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.68 | 2021-2023 | Botox, Qulipta, Ubrelvy |
| Argenx US, INC. | $240.17 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $237.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $136.85 | 2023 | Amvuttra, Onpattro |
| Idorsia Pharmaceuticals US INC | $121.87 | 2023 | Quviviq |
| Lilly USA, LLC | $117.06 | 2022-2023 | Amyvid |
| Fisher & Paykel Healthcare INC | $76.15 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.07 | 2022 | |
| Merz Pharmaceuticals, LLC | $45.31 | 2022-2023 | Xeomin |
| Ucb, INC. | $32.50 | 2023 | |
| Lundbeck LLC | $30.09 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.94 | 2025 | Lifevest |
| Mdd US Operations, LLC | $26.04 | 2022 | |
| Brainsway USA INC | $22.66 | 2022 | |
| Cala Health, INC. | $20.77 | 2023 | Cala Trio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.58 | 2023 | Ultomiris |
| Amneal Pharmaceuticals LLC | $14.73 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.